Immunotherapy alone beat chemo as first treatment for one type of advanced uterine cancer
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with advanced mismatch repair-deficient endometrial cancer went a median 38.2 months without progression on pembrolizumab alone, vs. 8.4 months…